TMA Precision Health
Rare-disease precision-medicine company using AI and expert review to shorten diagnostic journeys for genetically complex patients, including children.
What They Do
TMA Precision Health sells a tech-enabled precision-medicine service that helps health plans and clinical partners identify patients with suspected genetic disease and deliver genome-based treatment insights faster than the traditional rare-disease diagnostic process. The company's mission is rooted in pediatric rare disease and the experience of founder Josh Resnikoff's son, even though the current platform spans rare-disease patients more broadly rather than serving only children. Public materials position TMA as a workflow and insight layer for plans and healthcare organizations, not a direct-to-consumer genetics company. That makes it adjacent to PHD's pediatric landscape through rare disease and complex-child populations, but less squarely maternal-pediatric than the NICU-focused Springhood-linked companies.
Competitive Position
TMA competes with rare-disease diagnostics and genomics workflow companies such as GeneDx, Fabric Genomics, and other precision-medicine enablement vendors rather than with mainstream pediatric digital-health startups. Its differentiation is less about sequencing infrastructure itself and more about combining patient identification, clinical expertise, and actionable treatment guidance into a payer- and provider-facing service. For PHD, the company is strategically interesting because pediatric rare disease is a genuine child-health wedge, but the business is currently broader than the more clearly pediatric companies in Springhood's orbit.
Funding Rounds
No funding rounds on record for this company.